Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the va...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünwald, Viktor, Merseburger, Axel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390993/
https://www.ncbi.nlm.nih.gov/pubmed/22787405
http://dx.doi.org/10.2147/OTT.S23273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390993/
https://www.ncbi.nlm.nih.gov/pubmed/22787405
http://dx.doi.org/10.2147/OTT.S23273

Ejemplares similares